Trump rant likely to put pressure on healthcare sector

Published 12-JAN-2017 12:47 P.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Trump trumps his own share market rally with his first speech after the election indicating that he will bring to account ‘murderous’ pharmaceutical enterprises sending the sector into freefall and immediately wiping more than 100 points off the DOW.

President-elect Donald Trump’s victory has undoubtedly been largely responsible for boosting global equity markets, but his first address following the election was far from confidence inspiring, prompting a sharp fall in the DOW and an equally substantial spike in the Volatility Index (VIX).

While his vendetta against so-called murderous pharmaceutical companies – you can watch it here – triggered a sharp downturn in US healthcare stocks, it may also be his credibility that takes a hit as he is taken to task on references to Nazi Germany like media misrepresentation at work in the US on one hand, while refusing to answer questions from media companies who he labelled as dishonest, arguably a very similar form of controlling information.

Also, taking aim at his own intelligence agency for allowing information to be released for public scrutiny may not be considered as the type of commentary expected from the President of the world’s most powerful country.

However, markets stabilised in the afternoon session, albeit not recovering to previous highs, and the DOW has finished up circa 0.5%. The FTSE 100 was up 0.2% with the DAX gaining 0.5% and the CAC 40.

Consequently, on the score of index movements, these slight gains are unlikely to be a key driver of Australian markets, particularly given they could be tarnished by Trump’s impact on the volatility index.

The impact for Australian markets

No doubt, the S&P/ASX 200 Healthcare index (XHJ) will receive a hit given that many Australian biotechs and pharmaceutical companies are leveraged to US markets.

On a more positive note, commodities could provide support with a recovery in crude oil prices and continued strengthening in the gold price generating positive sentiment in those sectors. However, one aspect worth noting was the relatively significant increase in the Australian dollar against the US dollar, up more than 1% from US$0.736 to US$0.744 as US markets drew to a close.

This could put a dampener on recent strong gains by Australian gold producers given the strengthening in the Australian dollar against the US dollar translates into a lower Australian dollar gold price.

One of the most interesting commodity related developments was in the uranium space where the world’s largest uranium producer, Kazatomprom, announced yesterday that it would reduce planned uranium output in 2017 by 10%, representing approximately 3% of annual global output.

It has been reported that if this reduction were to remain in place for three years the supply/demand deficit would increase from next year onwards. Prior to this development many analysts were factoring in a relatively near-term recovery in the uranium price, so this is likely improve sentiment towards the sector.

It should be noted here that broker projections and price targets are only estimates and may not be met. Also, historical data in terms of earnings performance and/or share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.

It certainly rubbed off on ASX listed stocks yesterday with strong gains by Berkeley Energia (+5.5%), Paladin Energy (+6.5%), Deep Yellow (+25%) and Boss Resources (+20%).



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X